Search details
1.
Methodological considerations for observational studies of treatment effectiveness in neurology: a clinician's guide.
J Neurol Neurosurg Psychiatry
; 95(5): 454-460, 2024 Apr 12.
Article
in English
| MEDLINE | ID: mdl-37890986
2.
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 Mar 27.
Article
in English
| MEDLINE | ID: mdl-38538060
3.
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
J Neurol Neurosurg Psychiatry
; 2024 Jan 19.
Article
in English
| MEDLINE | ID: mdl-38242680
4.
Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study.
Eur J Neurol
; 31(3): e16174, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38085272
5.
Observational studies of treatment effectiveness in neurology.
Brain
; 146(12): 4799-4808, 2023 12 01.
Article
in English
| MEDLINE | ID: mdl-37587541
6.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Brain
; 146(11): 4633-4644, 2023 11 02.
Article
in English
| MEDLINE | ID: mdl-37369086
7.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(9): 707-717, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37068931
8.
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
J Neurol Neurosurg Psychiatry
; 94(12): 1004-1011, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37414534
9.
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Mult Scler
; 29(3): 326-332, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36800908
10.
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.
Eur J Neurol
; 30(4): 1014-1024, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36692895
11.
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
J Neurol Neurosurg Psychiatry
; 2022 Sep 30.
Article
in English
| MEDLINE | ID: mdl-36180218
12.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 93(12): 1330-1337, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36261289
13.
The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis.
J Theor Biol
; 541: 111091, 2022 05 21.
Article
in English
| MEDLINE | ID: mdl-35283184
14.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler
; 27(12): 1838-1851, 2021 10.
Article
in English
| MEDLINE | ID: mdl-33423618
15.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain
; 143(9): 2742-2756, 2020 09 01.
Article
in English
| MEDLINE | ID: mdl-32947619
16.
Early clinical markers of aggressive multiple sclerosis.
Brain
; 143(5): 1400-1413, 2020 05 01.
Article
in English
| MEDLINE | ID: mdl-32386427
17.
Spinal Tuberculosis: Clinicoradiological Findings in 274 Patients.
Clin Infect Dis
; 67(1): 89-98, 2018 06 18.
Article
in English
| MEDLINE | ID: mdl-29340585
18.
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Brain Behav
; 14(5): e3498, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38688877
19.
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
Lancet Child Adolesc Health
; 8(5): 348-357, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38547883
20.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
JAMA Neurol
; 80(8): 789-797, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37307006